Spread of breast cancer accelerates during sleep | 27-Jun-2022 | 07:00 | RNS |
Issue of Equity | 23-Jun-2022 | 18:24 | RNS |
Secured contract from pharma services customer | 22-Jun-2022 | 07:00 | RNS |
Predicting immunotherapy response in SCLC | 16-Jun-2022 | 07:00 | RNS |
Potential role of invasive cellular protrusions | 14-Jun-2022 | 07:00 | RNS |
Partnership with major United States urology group | 30-May-2022 | 07:00 | RNS |
Molecular characterisation of CTCs | 27-May-2022 | 07:00 | RNS |
Price Monitoring Extension | 25-May-2022 | 16:35 | RNS |
ANGLE receives FDA clearance for Parsortix | 25-May-2022 | 12:30 | RNS |
Prostate Cancer UK funds new study using Parsortix | 20-May-2022 | 07:00 | RNS |
Preliminary Results | 28-Apr-2022 | 07:00 | RNS |
Notice of Preliminary Results and Webcast | 20-Apr-2022 | 07:00 | RNS |
Poster on Parsortix system presented at AACR 2022 | 14-Apr-2022 | 07:00 | RNS |
Identifying drug targets in cancer metastasis | 01-Apr-2022 | 07:00 | RNS |
Rapid information on patient response to therapies | 29-Mar-2022 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 13.67p |
Change Today | -0.083p |
% Change | -0.61 % |
52 Week High | 31.35 |
52 Week Low | 9.24 |
Volume | 655,428 |
Shares Issued | 322.64m |
Market Cap | £44.09m |
RiskGrade | 312 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
12:59 | 36,546 @ 13.65p |
12:54 | 50,000 @ 13.64p |
12:54 | 50,000 @ 13.52p |
12:10 | 82,692 @ 13.65p |
12:04 | 150,000 @ 13.51p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research